Eikonizo Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
Developing First- and Best-in-Class disease-modifying therapeutics targeting HDAC6 to improve cellular health and function in people with neurodegenerative and cardiorenal disease Clinical candidate EKZ-102, our oral CNS-penetrant HDAC6 inhibitor is on track for IND in 2025
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}